Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status

Clinica Chimica Acta

Volumn 262, Issue 1-2, 1997, Pages 99-119

  Torregrosa, Dolores ^a   Bolufer, Pascual ^a   Lluch, Ana ^b   López, J Antonio ^a   Barragán, Eva ^a   Ruiz, Amparo ^c   Guillem, Vicente ^c   Munárriz, Blanca ^a   Conde, Javier García ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOT HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; LYMPH NODES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTRADIOL; SURVIVAL ANALYSIS;

EID: 0030990317     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)06542-X     Document Type: Article

References (39)

1. Dexter DL, Kowalsky HM, Blazer BA, Fligiel Z, Vogel RFCE, Heppner GH. Heterogeneity of tumour cells from a single mouse mammary tumour. Cancer Res 1974;38:3174-3181.
2. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987;10:5-9.
3. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984;311:483-486.
4. Bargmann GI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-229.
5. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987;1398-1402.
6. Klijn JG, Bems PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review of 5232 patients. Endocr Rev 1992:13:3-17.
7. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: Result of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29:41-49.
8. Natali PG, Nicotra M, Bigotti A et al. Expression of the p 185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-461:
9. Slamon DJ, Press NE, Godolphin W et al. Studies of the HER-2/neu protooncogene in human breast cancer. Cancer Cells 1989;7:371-384.
10. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235:177-182.
11. Borg A, Tandon AK, Sigurdsson H et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
12. Paik S, Kazan RFCE, Fischer ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
13. Tandon AK, Clark GM, Chamness GC et al. Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-1128.
14. Clark GM, McGuire WL. Follow up study of Her-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-948.
15. Wolman SR, Pauley RJ, Mohamed AN et al. Genetic markers as prognostic indicators in breast cancer. Cancer 1992;70:1765-1774
16. Kadowaki T, Kasuga M, Tobe K et al. A Mr-190,000 glycoprotein phosphorylation on tyrosine residues in epidermal growth factor stimulated Y.B cells is the product of the c-erbB-2 gene. Biochem Biophys Res Commun 1987;144:699-704
17. Gasparini G, Gullick WJ, Bevilacqua P et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy and conventional pathologic features. J Clin Oncol 1992;10:686-695.
18. Hainsworth PJ, Henderson MA, Stillwell RG, Bennet RC. Comparison of EGF-R, cerbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur J Surg Oncol 1991;17:9-15.
19. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 1992;164:323-326.
20. Wright CPS, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-2090.
21. Nicholson S, Wright C, Sainsbury JRC et al. Epidermal growth factor receptor (EGF-R), as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure: J steroid Biochem Molec Biol 1990;37:811-815.
22. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-377.
23. Bolufer P, Miralles F, Rodriguez A, Vazquez C, Lluch A. Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics. Eur J Cancer 1990;26:283-290.
24. Bolufer P, Molina R, Ruiz A, Hemandez M, Vazquez C, Lluch A. Estradiol receptor in combination with neu oncogene amplification might define new subtypes of breast cancer. Clin Chim Acta 1994;229:107-122.
25. Maniatis T, Fritsch E, Sambrook J. Molecular cloning. A laboratory manual. New York, Cold Spring Harbor Laboratory, 1982
26. Leake RE, Laing L, Smith DC. A role for nuclear estrogen receptors in prediction of therapy regime for breast cancer patients. In: King RJB ed. Steroid receptor assays in human breast tumors: Methodological and clinical aspects. Cardiff, Alpha Omega Press, 1979, 75-86.
27. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors (Commentary). J Natl Cancer Inst 1994;86:829-834.
28. Koenders PG, Beex LVAM, Kienhuis CBM, Kloppenborg PWC, Benraad TJ. Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 1993;25:21-27.
29. Nicholson RI, McClelland RA, Gee JMW et al. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Treat 1994;29:117-125.
30. Klijn JGM, Look MP, Portengen H, Alexieva-Figusch JA, van Putten WLJ, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Result of a 10 years follow-up study: Breast Cancer Res Treat 1994;29:73-83.
31. Toi M, Tominaga T, Osaki A, Toge T. Role of epidermal growth factor receptor expression in primary breast cancer: a result of a biochemical study and an immunocytochemical study: Breast Cancer Res Treat 1994;29:51-58.
32. Gasparini G, Boracchi P, Bevilacqua P, Mezzetti M, Pozza F, Weidner N. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma: Breast Cancer Res Treat 1994;29:59-71.
33. Spyratos F, Martin PM, Hacene K et al. Prognostic value of a solubilized fraction of FCE receptor in primary breast cancer using an immunoenzymatic assay. A retrospective study Breast Cancer Res Treat 1994:29:85-95.
34. Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H. Prognostic value of epidermal growth factor receptor in node positive breast cancer. Breast Cancer Res Treat 1989;14:77-90.
35. Nicholson S, Richard J, Sainsbury C.P.S. et al. Epidermal growth factor receptor (EGF-R); results of a 6 years follow-up study in operable breast cancer with emphasis on the node-negative subgroups. Br J Cancer 1991;63:146-150.
36. Delarue JC, Terrier P, Terrier-Lacombe MJ, Mouriesse H, Gotteland M, May-Levin F. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Bull Cancer 1994;81:1067-1077.
37. Toikkanen S, Helin R, Joensuu H. Prognostic significance of Her-2 oncoprotein soncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol 1992;10:1044-1048.
38. Tsuda R, Hirohashi S, Shimosato Y et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene co-amplification units:hstl/int 2, c-erbB-2/ear-l. Cancer Res 1989;49:3104-3108.
39. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human breast cancers. British Med Bul 1991;47:87-98.